SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Arthur Klausner to speak at the 13th Annual Drug Discovery & Development of Innovative Therapeutics (DDT) in Boston, MA
News | 08. 04. 2008
